Navigation Links
Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
Date:11/5/2013

therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the conference call and webcast to discuss financial results. 

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of our current compounds, AT-001, AT-002 and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability  to obtain regulatory approval for our existing or future product candidates;  the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key sc
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
7. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
11. Fate Therapeutics Strengthens Its iPSC Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... OMICS Group International invites researchers, ... in the ‘Open Access Week’ by actively contributing ... Group Pharma Journals from 20-26th October, 2014. ... emerging Sciences, accelerating with a tremendous speed to ... globe. The industry is gearing with innovation and ...
(Date:9/18/2014)... new microscopy technology that allows them to view ... , Dubbed "Complementation Activated Light Microscopy" (CALM), the ... order of magnitude finer than conventional optical microscopy, ... at the nanometer scale. , In a paper ... , the researchers behind CALM used it to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 September 24 ... City, MX. ASEA is the manufacturer of the world's ... skin care product, RENU28. , The Mexico City ... President Duvan Botero, and ASEA Field Leader Shawn Catmull ... a PhD in Atomic/Medical Physics from the University of ...
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2
... Bavituximab, Currently in Phase II Cancer Trials in Combination with ... Chemotherapy -, ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ...
... design offers enhanced convenience, ease-of-use, and helps optimize ... ... March 3 Metrex Research Corporation is,pleased to announce the newest ... unique patented design offers a new,easy-open/easy-close pull tab with slim, flexible ...
... Disposables, Services and Accessories Revenue Up 102% ... ST. LOUIS, March 3 Stereotaxis, Inc. (Nasdaq:,STXS) ... full year,ended December 31, 2007., For the full ... $27.2 million in 2006. Sales of the Niobe(TM) system ...
Cached Biology Technology:Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 2Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 4Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 5CaviWipes(R): Taking Surface Disinfection to a New Level 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:9/18/2014)... small, icy moon of Uranus, is one of the ... system. Despite its relatively small size, Miranda appears to ... in the formation of at least three remarkable and ... , These coronae are visible in Miranda,s southern hemisphere, ... Arden corona, the largest, has ridges and troughs with ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... For the first time, a study by researchers at Columbia ... post-traumatic stress disorder (PTSD) among adults. The study of male ... the association between asthma and PTSD is not primarily explained ... twin pairs, who had lived together in childhood, and who ...
... N.Y. Single-molecule biologythe revolutionary field that deals ... Tremendous technical advances have made it possible to ... images as they twist, twirl, wobble, and unfold. ... book that was just released by Cold Spring Harbor ...
... MADISON - When University of Wisconsin-Madison researchers succeeded in ... they also began to redefine the political and ethical ... Alta Charo, a UW-Madison professor of law and bioethics, ... the social dimensions of the ongoing controversy over embryonic ...
Cached Biology News:Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study 2New book presents methods to poke and prod individual molecules 2Reprogramming the debate: stem-cell finding alters ethical controversy 2Reprogramming the debate: stem-cell finding alters ethical controversy 3
... Immunogen: Synthetic peptide derived from an ... mTOR (Mammalian target of rapamycin FRAP RAFT1 ... mTOR protein. On Western blots it ... Reactivity: Human (positive control: HEK293 cell ...
MW5...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: